📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
5 articles scientifiques publiés — formation continue solide
Référence presse grand public
Cité 4 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Paris Normandie · 02/08/2025
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQWVlFVnB0MXNrOFdYc0NxZWNiMU8weFRsaWZtRUplWExmcTdQbmtIQm1BSTVXQnFiNXFWeTQ3dmtVNlNrRXFnbFhPOGJFMFVpcjV1QVd1dG1Od3JrcWFFSm04UkZEZnVxSXJNdXQyZFdtTHJ5NWZpRVpYazdnOFQ5VXlYMVA1MmFqbS1yZGpzWk54LWxHWGRvQTl4YzdXUElTeWREcENzLUF2MGJTc0pyYkFxZUNKb29IYX
📰 reforme.net · 19/05/2025
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxObGJJMHZJSlFiRlBFTW13am1kYTdWUFRMVVBRVTk3UUQtSjlHN0JhcjRBal80N29vYnN3RHRybDZNWFV1X0E4VGlGX0I5QmFieklrSGl2aXNuMTJldDg3N2VfTUgzN256bElBTkUzdTN6TmJlblJxR0N4bWNsZ2VSTUNIMWtoa3hURUx3UVVYSThoZ0JIX2ZsbWwtZGpYdkp2WUJ0Tk1PeElVcGRnQjlHcHV3WHhyMk1VeT
📰 Paris Normandie · 06/10/2024
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxPSmdWZGc4MUJIbEtCRkQyNG1KMm1FUmY5NDdmbVNlWHcxOXVsLTNLVEkwNUotbFZ5bFIwUm5IZ245QUZPSGV3SmNtMzF6TU9SNVhiOEJLRkdKeUFvM1FNWHBaWm8xSzVtOU5HZTRhcjhhVUpxbUh5cnBZbDdaMVJoSzdkbTYzbDdORTc5aEdObDE0dm5jelNXNnNqZy1tXzVFVGI2Q09RY3Y1ZjM4TGpwNkFEaExyeHdhVn
📰 lecourriercauchois.fr · 28/04/2017
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNNzVqUXJldkMwcXJhQlQwMlBveFJyVG5UNkxXdjlzeFctWnFKcnVmWjI5UU5qcnBKT0xjVmtGamNMSWZhdHEzR3ZVbGNfWU1najFCWTNsVHRxZFowOVJYNy1lbHNIVXczV0VPcjZFTmctblEzYTFBMXp5TkJJcG1xa2U3T1pPZ0p4ZHRoOTItNDAwcWd1MjUzSGFzUjFnWC1tNGw2XzIybVQ?oc=5" target="_blank">
European respiratory review : an official journal of the European Respiratory Society · 2013
By 2020, chronic obstructive pulmonary disease (COPD) will be the third cause of mortality. Extrapulmonary comorbidities influence the prognosis of patients with COPD. Tobacco smoking is a common risk factor for many comorbidities, including coronary heart disease, heart failure and lung cancer. Comorbidities such as pulmonary artery disease and malnutrition are directly caused by COPD, whereas others, such as systemic venous thromboembolism, anxiety, depression, osteoporosis, obesity, metabolic syndrome, diabetes, sleep disturbance and anaemia, have no evident physiopathological relationship with COPD. The common ground between most of these extrapulmonary manifestations is chronic systemic inflammation.All of these diseases potentiate the morbidity of COPD, leading to increased hospitalisations and healthcare costs. They can frequently cause death, independently of respiratory failure. Comorbidities make the management of COPD difficult and need to be evaluated and treated adequately.
European respiratory review : an official journal of the European Respiratory Society · 2019
The increasingly female face of chronic obstructive pulmonary disease (COPD) prevalence among women has equalled that of men since 2008, due in part to increased tobacco use among women worldwide and exposure to biomass fuels. This finding is supported by a number of characteristics. There is evidence of susceptibility to smoking and other airborne contaminants, along with epidemiological and phenotypic manifestations. COPD has thus become the leading cause of death in women in the USA. The clinical presentation is characterised by increasingly pronounced dyspnoea with a marked tendency towards anxiety and depression, undernutrition, nonsmall cell lung cancer (especially adenocarcinoma) and osteoporosis. Quality of life is also more significantly impacted. The theories advanced to explain these differences involve the role played by oestrogens, impaired gas exchange in the lungs and smoking habits. While these differences require appropriate therapeutic responses (smoking cessation, pulmonary rehabilitation, long-term oxygen therapy), barriers to the treatment of women with COPD include greater under-diagnosis than in men, fewer spirometry tests and medical consultations. Faced with this serious public health problem, we need to update and adapt our knowledge to the epidemiological changes.
Journal for immunotherapy of cancer · 2020
Background As the immune system is compromised in patients with cancer, therapeutic strategies to stimulate immunity appear promising, to avoid relapse and increase long-term overall survival. Interleukin-15 (IL-15) has similar properties to IL-2, but does not cause activation-induced cell death nor activation and proliferation of regulatory T cells (Treg), which makes it a serious candidate for anticancer immunotherapy. However, IL-15 has a short half-life and high doses are needed to achieve responses. Designed to enhance its activity, receptor-linker-IL-15 (RLI) (SO-C101) is a fusion molecule of human IL-15 covalently linked to the human IL-15Rα sushi+ domain currently assessed in a phase I/Ib clinical trial on patients with advanced/metastatic solid cancer. Methods We investigated the antimetastatic activity of RLI in a 4T1 mouse mammary carcinoma that spontaneously metastasizes and evaluated its immunomodulatory role in the metastatic lung microenvironment. We further characterized the proliferation, maturation and cytotoxic functions of natural killer (NK) cells in tumor-free mice treated with RLI. Finally, we explored the effect of RLI on human NK cells from healthy donors and patients with non-small cell lung cancer (NSCLC). Results RLI treatment displayed antimetastatic properties in the 4T1 mouse model. By characterizing the lung microenvironment, we observed that RLI restored the balance between NK cells and neutrophils (CD11b+ Ly6Ghigh Ly6Clow) that massively infiltrate lungs of 4T1-tumor bearing mice. In addition, the ratio between NK cells and Treg was strongly increased by RLI treatment. Further pharmacodynamic studies in tumor-free mice revealed superior proliferative and cytotoxic functions on NK cells after RLI treatment compared with IL-15 alone. Characterization of the maturation stage of NK cells demonstrated that RLI favored accumulation of CD11b+ CD27high KLRG1+ mature NK cells. Finally, RLI demonstrated potent immunostimulatory properties on human NK cells by inducing proliferation and activation of NK cells from healthy donors and enhancing cytotoxic responses to NKp30 crosslinking in NK cells from patients with NSCLC. Conclusions Collectively, our work demonstrates superior activity of RLI compared with rhIL-15 in modulating and activating NK cells and provides additional evidences for a therapeutic strategy using RLI as antimetastatic molecule.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal for immunotherapy of cancer · 2020 · Comparative Study
Desbois M, Béal C, Charrier M, Besse B, et al.
Revue des maladies respiratoires · 2008 · English Abstract
Underner M, Hadjadj S, Beauchant M, Bridoux F, et al.
Current medical research and opinion · 1983 · Clinical Trial
Meurice J
European respiratory review : an official journal of the European Respiratory Society · 2019 · Journal Article
Gut-Gobert C, Cavaillès A, Dixmier A, Guillot S, et al.
European respiratory review : an official journal of the European Respiratory Society · 2013 · Journal Article
Cavaillès A, Brinchault-Rabin G, Dixmier A, Goupil F, et al.